Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.54 |
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | PPARD | Q03181 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 7/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575619 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL2345376 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL336842 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL1333784 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL347119 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL2483372 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL22612557 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL22612553 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL22612525 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL346960 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022115651-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | HEPION PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-8765809-B2 | Ester derivative and use thereof | AJINOMOTO CO., INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130053441-A1 | NOVEL ESTER DERIVATIVE AND USE THEREOF | AJINOMOTO CO., INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-8212068-B2 | Ester derivative and use thereof | AJINOMOTO CO., INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090170942-A1 | ESTER DERIVATIVE AND USE THEREOF | AJINOMOTO CO. INC (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1689827-B1 | ADDITIVE COMPONENTS FOR LIQUID CRYSTALLINE MATERIALS | ROLIC AG (CH) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053441-A1 | NOVEL ESTER DERIVATIVE AND USE THEREOF | MEP1A, CES2, MEP1B | FFAR4 641/4885FFAR1 295/4885ALDH1A1 2688/4885 |
| US-20090170942-A1 | ESTER DERIVATIVE AND USE THEREOF | MEP1A, CES2, F8 | FFAR4 979/4885FFAR1 449/4885ALDH1A1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.